Login / Signup

Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy.

Motoo NomuraTaisuke HosokaiMasashi TamaokiAkira YokoyamaShigemi MatsumotoManabu Muto
Published in: Esophagus : official journal of the Japan Esophageal Society (2023)
The timing of the infusion of nivolumab may affect treatment efficacy in R/M-ESCC.
Keyphrases
  • squamous cell carcinoma
  • low dose
  • small cell lung cancer
  • lymph node metastasis
  • combination therapy
  • replacement therapy